Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial

Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial

<b>Background</b>: pGX9501 is a prophylactic DNA vaccine encoding the spike protein of SARS-CoV-2 and can induce immune response in the human body so as to prevent COVID-19. With respect to non-clinical studies, pGX9501 has been demonstrated to induce both cellular and humoral immune res...

Full description

Saved in:
Bibliographic Details
Main Authors: Haijing Yang, Yang Zhou, Xin Cheng, Chao Qiu, Shuo Wang, Yu Xia, Xuefen Huai, Zhenning Xiu, Jiarong Wang, Yue He, Guoying Cao, Qiong Wei, Jingjing Wang, Jingwen Ai, Haochen Zhang, Yi Zhang, Jing Zhang, Wenhong Zhang, Bin Wang
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Vaccines
Subjects:
COVID-19
SARS-CoV-2
DNA vaccine
pGX9501(INO-4800)
acute respiratory disease
Online Access:https://www.mdpi.com/2076-393X/13/6/573
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.mdpi.com/2076-393X/13/6/573

Similar Items